TY - STD TI - World Health Organization. http://www.who.int/hiv/topics/hepatitis. Accessed July 2017. UR - http://www.who.int/hiv/topics/hepatitis ID - ref1 ER - TY - JOUR AU - Smith, C. J. AU - Ryom, L. AU - Weber, R. AU - Morlat, P. AU - Pradier, C. AU - Reiss, P. PY - 2014 DA - 2014// TI - Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:a:D): a multicohort collaboration JO - Lancet VL - 384 UR - https://doi.org/10.1016/S0140-6736(14)60604-8 DO - 10.1016/S0140-6736(14)60604-8 ID - Smith2014 ER - TY - JOUR AU - Weber, R. AU - Ruppik, M. AU - Rickenbach, M. AU - Spoerri, A. AU - Furrer, H. AU - Battegay, M. PY - 2013 DA - 2013// TI - Decreasing mortality and changing patterns of causes of death in the Swiss HIV cohort study JO - HIV Med VL - 14 UR - https://doi.org/10.1111/j.1468-1293.2012.01051.x DO - 10.1111/j.1468-1293.2012.01051.x ID - Weber2013 ER - TY - JOUR AU - Re, L. R. AU - Kallan, M. J. AU - Tate, J. P. AU - Localio, A. R. AU - Lim, J. K. AU - Goetz, M. B. PY - 2014 DA - 2014// TI - Hepatic decompensation in antiretroviral-treated HIV/hepatitis C-Coinfected compared to hepatitis C-Monoinfected patients: a cohort study JO - Ann Intern Med VL - 160 UR - https://doi.org/10.7326/M13-1829 DO - 10.7326/M13-1829 ID - Re2014 ER - TY - JOUR AU - Graham, C. S. AU - Baden, L. R. AU - Yu, E. AU - Mrus, J. M. AU - Carnie, J. AU - Heeren, T. PY - 2001 DA - 2001// TI - Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis JO - Clin Infect Dis VL - 33 UR - https://doi.org/10.1086/321909 DO - 10.1086/321909 ID - Graham2001 ER - TY - JOUR AU - Chen, J. Y. AU - Feeney, E. R. AU - Chung, R. T. PY - 2014 DA - 2014// TI - HCV and HIV co-infection: mechanisms and management JO - Nat Rev Gastroenterol Hepatol VL - 11 UR - https://doi.org/10.1038/nrgastro.2014.17 DO - 10.1038/nrgastro.2014.17 ID - Chen2014 ER - TY - JOUR AU - Mira, J. A. AU - Rivero-Juárez, A. AU - López-Cortés, L. F. AU - Girón-González, J. A. AU - Téllez, F. AU - de los Santos-Gil, I. PY - 2013 DA - 2013// TI - Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis JO - Clin Infect Dis VL - 56 UR - https://doi.org/10.1093/cid/cit103 DO - 10.1093/cid/cit103 ID - Mira2013 ER - TY - JOUR AU - Arends, J. E. AU - Lieveld, F. I. AU - Boeijen, L. L. AU - Kanter, C. T. M. M. AU - Erpecum, K. J. AU - Salmon, D. PY - 2015 DA - 2015// TI - Natural history and treatment of HCV/HIV coinfection: is it time to change paradigms? JO - J Hepatol VL - 63 UR - https://doi.org/10.1016/j.jhep.2015.06.034 DO - 10.1016/j.jhep.2015.06.034 ID - Arends2015 ER - TY - JOUR AU - Cachay, E. AU - Soriano, V. PY - 2016 DA - 2016// TI - Is HIV still a special population for the treatment of hepatitis C? JO - AIDS VL - 30 UR - https://doi.org/10.1097/QAD.0000000000001135 DO - 10.1097/QAD.0000000000001135 ID - Cachay2016 ER - TY - STD TI - Langness J, Larson B, Bayer J, Rogers M, Kiser J. Readying HIV/HCV coinfected patients for HCV treatment: occurrence and management of antiviral interactions. In: 16th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy. 2015, Washington. Abstract 18. http://regist2.virology-education.com/2015/16HIVHEP/34_Langness.pdf. Accessed Dec 2016. UR - http://regist2.virology-education.com/2015/16HIVHEP/34_Langness.pdf ID - ref10 ER - TY - JOUR AU - Naggie, S. AU - Cooper, C. AU - Saag, M. AU - Workowski, K. AU - Ruane, P. AU - Towner, W. J. PY - 2015 DA - 2015// TI - Ledipasvir and Sofosbuvir for HCV in patients Coinfected with HIV-1 JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1501315 DO - 10.1056/NEJMoa1501315 ID - Naggie2015 ER - TY - JOUR AU - Butt, A. A. AU - Yan, P. AU - Shaikh, O. S. AU - Chung, R. T. AU - Sherman, K. E. PY - 2016 DA - 2016// TI - Sofosbuvir-based regimens in clinical practice achieve SVR rates closer to clinical trials: results from ERCHIVES JO - Liver Intent VL - 36 UR - https://doi.org/10.1111/liv.13036 DO - 10.1111/liv.13036 ID - Butt2016 ER - TY - JOUR AU - El-Sherif, O. AU - Khoo, S. AU - Solas, C. PY - 2015 DA - 2015// TI - Key drug-drug interactions with direct-acting antiviral in HIV-HCV coinfection JO - Curr Opin HIV AIDS VL - 10 UR - https://doi.org/10.1097/COH.0000000000000185 DO - 10.1097/COH.0000000000000185 ID - El-Sherif2015 ER - TY - STD TI - German P, Garrison K, Pang PS, Stamm LM, Ray AS, Shen G, et al. Drug-Drug Interactions Between Anti-HCV Regimen Ledipasvir/Sofosbuvir and Antiretrovirals. In: Conference on Retroviruses and Opportunistic Infections. 2015, Seattle. Abstract 82. http://www.croiconference.org/sessions/drug-drug-interactions-between-anti-hcv-regimen-ledipasvirsofosbuvir-and-antiretrovirals. Accessed Dec 2016. UR - http://www.croiconference.org/sessions/drug-drug-interactions-between-anti-hcv-regimen-ledipasvirsofosbuvir-and-antiretrovirals ID - ref14 ER - TY - JOUR PY - 2017 DA - 2017// TI - EASL recommendations on treatment of hepatitis C 2016 JO - J Hepatol VL - 66 UR - https://doi.org/10.1016/j.jhep.2016.09.001 DO - 10.1016/j.jhep.2016.09.001 ID - ref15 ER - TY - STD TI - AASLD/IDSA HCV Guidance Panel. AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. http://www.hcvguidelines.org. Accessed July 2017. UR - http://www.hcvguidelines.org ID - ref16 ER - TY - JOUR AU - Kaur, K. AU - Gandhi, M. A. AU - Slish, J. PY - 2015 DA - 2015// TI - Drug-Drug Interactions Among Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Medications JO - Infect Dis Ther VL - 4 UR - https://doi.org/10.1007/s40121-015-0061-2 DO - 10.1007/s40121-015-0061-2 ID - Kaur2015 ER - TY - JOUR AU - Bhattacharya, D. AU - Belperio, P. S. AU - Shahoumian, T. A. AU - Loomis, T. P. AU - Goetz, M. B. AU - Mole, L. A. PY - 2017 DA - 2017// TI - Effectiveness of All-Oral Antiviral Regimens in 996 Human Immunodeficiency Virus/Hepatitis C Virus Genotype 1-Coinfected Patients Treated in Routine Practice JO - Clin Infect Dis VL - 64 UR - https://doi.org/10.1093/cid/cix111 DO - 10.1093/cid/cix111 ID - Bhattacharya2017 ER - TY - JOUR AU - Taramasso, L. AU - Ricci, E. AU - Celesia, B. M. AU - Bonfanti, P. AU - Quirino, T. AU - Squillace, N. PY - 2017 DA - 2017// TI - Co-administration of tenofovir plus protease inhibitor based antiretroviral therapy during sofosbuvir/ledipasvir treatment for HCV infection: much ado about nothing? JO - Clin Res Hepatol Gastroenterol VL - S2210-7401 ID - Taramasso2017 ER - TY - JOUR AU - Bunnell, K. L. AU - Vibhakar, S. AU - Glowacki, R. C. AU - Gallagher, M. A. AU - Osei, A. M. AU - Huhn, G. PY - 2016 DA - 2016// TI - Nephrotoxicity associated with concomitant use of Ledipasvir-Sofosbuvir and Tenofovir in a patient with hepatitis C virus and human immunodeficiency virus coinfection JO - Pharmacotherapy VL - 36 UR - https://doi.org/10.1002/phar.1803 DO - 10.1002/phar.1803 ID - Bunnell2016 ER - TY - STD TI - ClinicalTrials.gov. Effects of Sofosbuvir/Ledipasvir Treatment on the Pharmacokinetics and Renal Safety of Tenofovir. https://clinicaltrials.gov/ct2/show/NCT02588287. Accessed July 2017. UR - https://clinicaltrials.gov/ct2/show/NCT02588287 ID - ref21 ER -